METHOTREXATE INJECTION, BP 20 MG / 0.8 ML
METHOTREXATE (METHOTREXATE SODIUM) : 20 MG / 0.8 ML · DIN 02422190 · PHARMASCIENCE INC
Health Canada status: MARKETED
What is METHOTREXATE INJECTION, BP?
METHOTREXATE INJECTION, BP 20 MG / 0.8 ML contains METHOTREXATE (METHOTREXATE SODIUM) : 20 MG / 0.8 ML. It is listed in the Health Canada Drug Product Database under DIN 02422190, held by PHARMASCIENCE INC, supplied as SOLUTION for INTRAVENOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 12-Sep-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is METHOTREXATE INJECTION, BP used for?
Disease Modifying Antirheumatic Drug (DMARD) for severe disabling psoriasis, psoriatic arthritis, rheumatoid arthritis (RA), and seronegative arthritides. NOT for neoplastic diseases.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02422190 |
|---|---|
| Brand name | METHOTREXATE INJECTION, BP |
| Generic / active ingredient | METHOTREXATE (METHOTREXATE SODIUM) : 20 MG / 0.8 ML |
| Manufacturer | PHARMASCIENCE INC |
| Strength | 20 MG / 0.8 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS ; INTRAMUSCULAR |
| Schedule | Prescription |
| ATC code | L01BA01 METHOTREXATE |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 12-Sep-2024 |
| Original market date | 2014-05-08 00:00:00 |
How is it administered?
Weekly dosing only for RA and psoriasis. Psoriasis: 10-25 mg/week IM/IV. RA: Starting doses adjusted to response, usually not exceeding 20 mg/week. Administered by health professionals.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (refer to section 11), but typically requires protection from light and specific temperature controls.
How is it supplied?
1 mL glass pre-filled syringes containing 0.3 mL (7.5 mg), 0.4 mL (10 mg), 0.6 mL (15 mg), 0.8 mL (20 mg), or 1.0 mL (25 mg) of solution. Available in single cartons.
Contraindications
Hypersensitivity; severe renal impairment; pregnancy; nursing mothers; alcoholism/chronic liver disease; immunodeficiency; pre-existing blood dyscrasias; nitrous oxide anesthesia.
Warnings and precautions
Fatal toxicities with daily instead of weekly dosing. Serious bone marrow suppression, gastrointestinal toxicity, and hepatotoxicity (fibrosis/cirrhosis). Potential for lung disease.
Is METHOTREXATE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by ACCORD HEALTHCARE INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code L01BA01 METHOTREXATE. 20 of 51 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-METHOTREXATE | 2.5 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02509067 |
| APO-METHOTREXATE | 2.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02182963 |
| JAMP METHOTREXATE TABLETS | 10 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02553740 |
| M-METHOTREXATE | 2.5 MG | TABLET | MANTRA PHARMA INC | MARKETED | DIN 02534916 |
| METHOTREXATE INJECTION BP | 25 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02474891 |
| METHOTREXATE INJECTION BP | 25 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02327236 |
| METHOTREXATE INJECTION BP | 25 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02464365 |
| METHOTREXATE INJECTION BP | 25 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02474735 |
| METHOTREXATE INJECTION USP | 10 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02182947 |
| METHOTREXATE INJECTION USP | 25 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02182777 |
Who else supplies METHOTREXATE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. METHOTREXATE appears in 251 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.